You just read:

Health Canada approves oral treatment (Pr)AFINITOR® (everolimus) for progressive, non-functional GI and lung neuroendocrine tumours (NET)

News provided by

Novartis Pharmaceuticals Canada Inc.

Jul 11, 2016, 05:59 ET